Trio Health presents novel HBV, HCV therapy findings at The Liver Meeting

Trio Health presented results from four studies at The Liver Meeting 2019 that showed novel outcomes in patients treated for hepatitis B with Vemlidy or hepatitis C with Vosevi.
“Since our initial HCV studies in 2013, we’ve observed repeating themes across diseases where new, more efficacious, and safer therapies have been approved; namely, challenges in access to these therapies, understanding potential effects of long-term treatment with newer therapies, and potential concerns with the use of these therapies in diseases with changing population demographics,” Scott

Source link

Related posts

A Mechanistic Insight Into The Role Of Gut Microbiota In The Pathogenesis Of Primary Sclerosing Cholangitis


Public Service Loan Forgiveness Program Has Uncertain Future


Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy